	US 11,944,665 B2
	Methods and compositions for modulating lymphatic vessels in the central nervous system
Jonathan Kipnis, Charlottesville, VA (US); Antoine Louveau, Charlottesville, VA (US); and Sandro Da Mesquita, Charlottesville, VA (US)
Assigned to University of Virginia Patent Foundation, Charlottesville, VA (US)
Appl. No. 16/306,483
Filed by University of Virginia Patent Foundation, Charlottesville, VA (US)
PCT Filed May 31, 2017, PCT No. PCT/US2017/035285 § 371(c)(1), (2) Date Nov. 30, 2018, PCT Pub. No. WO2017/210343, PCT Pub. Date Dec. 7, 2017.
Claims priority of provisional application 62/344,164, filed on Jun. 1, 2016.
Prior Publication US 2019/0269758 A1, Sep. 5, 2019
Int. Cl. A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61K 41/00 (2020.01); A61N 5/06 (2006.01); A61P 25/00 (2006.01); A61P 25/28 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); A61N 5/067 (2006.01)

CPC A61K 38/1866 (2013.01) [A61K 38/1709 (2013.01); A61K 38/1825 (2013.01); A61K 41/0057 (2013.01); A61K 41/0071 (2013.01); A61N 5/062 (2013.01); A61P 25/00 (2018.01); A61P 25/28 (2018.01); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); A61N 5/067 (2021.08)]

3 Claims

1. A method of increasing flow of fluid in the central nervous system (CNS) of a subject, wherein the subject has a disease or disorder selected the group consisting of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), meningitis, and autism, the method comprising:

administering an effective amount of a Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) agonist to a meningeal space of the subject, wherein the VEGFR3 agonist is VEGF-c156S, wherein said administration is effective to increase fluid flow in the central nervous system of the subject as compared to pre-administration of the VEGFR3 agonist.